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In the voltage-gated Na+ channel the central pore is
believed to be lined by the S6 segments of all four
domains. Conformational changes of these S6 segments
are thought to give rise to channel opening, closing and
fast inactivation (FI). Whereas FI most likely occurs by an
occlusion of the intracellular part of the pore, the selectiv-
ity filter of the channel is located in the extracellular vesti-
bule. We sought to investigate possible interactions
between the selectivity filter and the intracellular part of
the domain IV S6 segment which is known be involved in
FI. To this end, a critical residue within the selectivity filter
of the rNaV1.4 channel, K1237 was replaced by the nega-
tively charged glutamate (K1237E). This mutation was
combined with serial cysteine replacements of amino
acids in the S6 segment of domain IV. In K1237E the mid-
point of FI (V05) was shifted to the hyperpolarized direc-
tion relative to wild-type (-60 ± 13 vs. -47 ± 11 mV, n = 6,
p < 0.01). Mutations of 16 residues in the domain IV-S6
produced inconsistent changes of V05. However, when
these mutations were combined with K1237E, V05 was
shifted to more negative values in all but one double
mutants (mean shift -13 mV), irrespective of the direction
and the amount of shift produced by the single S6 muta-
tion. Conclusion: The selectivity filter of the voltage-gated
Na+ channel is coupled to the machinery of FI.
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